Results 91 to 100 of about 6,040 (212)

Rimonabant, a potent CB1 cannabinoid receptor antagonist, is a G alpha(i/o) protein inhibitor [PDF]

, 2018
Rimonabant is a potent and selective cannabinoid CB1 receptor antagonist widely used in animal and clinical studies. Besides its antagonistic properties, numerous studies have shown that, at micromolar concentrations rimonabant behaves as an inverse ...
M. Paola Castelli, M Paola Castelli, Melis, Miriam, Rostislav Turecek, Ignazia Mocci, Gessa, Gian Luigi, Gian Luigi Gessa, Castelli, M. Paola, Mocci, Ignazia, Bernhard Bettler, Celine Ullrich, Turecek, Rostislav, Porcu, Alessandra, Ullrich, Celine, Bettler, Bernhard, Alessandra Porcu, Miriam Melis   +16 more
core   +1 more source

Rimonabant: From RIO to Ban

, 2020
Endocannabinoid antagonism as a treatment for obesity and the metabolic syndrome became a hugely anticipated area of pharmacology at the start of the century.
Amir H Sam, Mohammad A Ghatei, Victoria Salem   +2 more
core  

Endocannabinoid receptor blockade reduces alanine aminotransferase in polycystic ovary syndrome independent of weight loss

BMC Endocrine Disorders, 2017
Background Evidence suggests that endocannabinoid system activation through the cannabinoid receptor 1 (CB1) is associated with enhanced liver injury, and CB1 antagonism may be beneficial.
Alison J. Dawson, Eric S. Kilpatrick, Anne-Marie Coady, Abeer M. M. Elshewehy, Youssra Dakroury, Lina Ahmed, Stephen L. Atkin, Thozhukat Sathyapalan   +7 more
doaj   +1 more source

Bioactivation of the Cannabinoid Receptor Antagonist Rimonabant to a Cytotoxic Iminium Ion Metabolite

, 2016
The cannabinoid type 1 receptor (CB1r) antagonist rimonabant was approved in 2006 for the treatment of obesity but was withdrawn in 2008 due to serious drug-related psychiatric disorders.
Lucy H. Prime (2001757), Frida Gustafsson (2001751), Emre M. Isin (1599604), J. Gerry Kenna (2001748), Alison J. Foster (2001754), David G. Temesi (2001739), Neal Castagnoli (2001745), Johanna Midlöv (2001742)   +7 more
core   +1 more source

Monlunabant in adults with obesity and metabolic syndrome: Open‐label extension of a phase 2a trial

Diabetes, Obesity and Metabolism, Volume 28, Issue 5, Page 4366-4371, May 2026.
Filip K. Knop, George Kunos, Dror Dicker, Jean‐Sebastien Paquette, Louis Aronne, Oscar Birkhan, Ofir Frenkel, Thomas Holst‐Hansen, Karine Lalonde, Glenn Crater, for the trial investigators   +10 more
wiley   +1 more source

What is the future for rimonabant in the treatment of obesity

, 2008
Orlistat and sibutramine only cause modest reductions in body weight. Rimonabant, a cannabinoid receptor 1 antagonist, is a new approach to weight reduction, but is it safe, efficacious, and better than the existing ...
Doggrell, Sheila
core  

Rimonabant induced anorexia in rodents is not mediated by vagal or sympathetic gut afferents

, 2009
The selective CB1 receptor antagonist rimonabant is a novel weight control agent. Although CB1 receptors and binding sites are present in both the rodent central and peripheral nervous systems, including the afferent vagus nerve, the role of gut ...
Larsen, Philip J, van de Wall, Esther H.E.M., Jelsing, Jacob, Schwartz, Gary J, Vrang, Niels, Madsen, Andreas Nygaard   +5 more
core   +1 more source

Pooled analysis of three randomized, double‐blind, placebo controlled trials with rimonabant for smoking cessation [PDF]

, 2018
Despite the withdrawal of CB1 antagonists, such as rimonabant, from the market and from active clinical development because of concerns about their side effect profiles, research suggests that the endocannabinoid system may play an important role in ...
Anthenelli, Robert M, Robinson, Jason D, Dale, Lowell C, Cinciripini, Paul M, Aubin, Henri‐Jean, Karam‐Hage, Maher, Niaura, Raymond, Group, the STRATUS   +7 more
core   +1 more source

Cannabinoid-1 receptor antagonist rimonabant (SR141716) increases striatal dopamine D2 receptor availability

, 2013
The cannabinoid 1 receptor antagonist rimonabant (SR141716) alters rewarding properties and intake of food and drugs. Additionally, striatal dopamine D2 receptor (DRD2) availability has been implicated in reward function.
van den Brink, W., Vanderschuren, Louk J. M. J., de Bruin, K., Booij, Jan, Booij, J., Schulz, S., de Bruin, Kora, Dep of Animals in Science and Society, Schulz, Sybille, van der Giessen, E., Emotion and Cognition, Vanderschuren, L.J.M.J., Crunelle, C.L., van de Giessen, Elsmarieke, van den Brink, Wim, Crunelle, Cleo L.   +15 more
core   +1 more source

Effect of rimonabant on blood pressure in overweight/obese patients with/without co-morbidities: analysis of pooled RIO study results. [PDF]

, 2008
peer reviewedOBJECTIVE: Rimonabant, the first selective cannabinoid type 1 (CB1) receptor blocker, has been shown to improve multiple cardiometabolic risk factors in overweight/obese patients.
Despres, Jean-Pierre, Scheen, André, Pi-Sunyer, Xavier, Van Gaal, Luc, Mancia, Guiseppe, Ruilopea, Luis M., Scheen, Andr\ue9, Manciae, Guiseppe, Zanchetti, Alberto, Ruilope, Luis M   +9 more
core   +1 more source